Published in Gene Therapy Weekly, November 20th, 1995
In general terms, enhanced immune reactions against tumors is therapeutically useful. However, research with adenoviral vectors has shown that host immune responses against the vector limits the efficacy and persistence of gene expression.
Ashraf A. Elshami et al. questioned the effect of the host immune response against adenoviruses on cancer gene therapy with HSVtk gene delivery by an adenovirus vector followed by ganciclovir treatment in an animal model ("The Role of Immunosuppression in the Efficacy...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.